Recruitment

Recruitment Status
Completed

Inclusion Criteria

staging of a known recurrence
Patients over 18 years
Patient who have received in a lower range than 2 months of cervico-thoraco-abdominal-pelvic CT and scintigraphy in OctréoScan®
...
staging of a known recurrence
Patients over 18 years
Patient who have received in a lower range than 2 months of cervico-thoraco-abdominal-pelvic CT and scintigraphy in OctréoScan®
Patient who is suspected of endocrine tumors according to symptomatology, biology or imaging or pathological context (multiple endocrine neoplasia type 1)
initial staging: this includes research multifocal disease or locoregional or metastatic extension if well-differentiated neuroendocrine tumor (grade 1 et/ou 2)
Patient affiliated or beneficiary of regime of social security of a Member State of the European community
Search occult recurrence or suspicion of recurrence (clinical, laboratory, imaging doubtful)
Search of the primary tumor, especially in the case of the inaugural discovery of metastases
Patient who have signed an informed consent

Exclusion Criteria

Pregnant or lactating woman
Persons placed under judicial protection
Patient with another evolutive cancer disease and/or treated for less than 5 years
...
Pregnant or lactating woman
Persons placed under judicial protection
Patient with another evolutive cancer disease and/or treated for less than 5 years
Patient unable to give their free and informed consent
Premenopausal woman without effective contraception (estrogen-progestin or intrauterine contraceptive device)

Summary

Conditions
Neuroendocrine Tumors
Type
Observational
Design
  • Observational Model: Case-Only
  • Time Perspective: Prospective

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Inclusion Criteria

staging of a known recurrence
Patients over 18 years
Patient who have received in a lower range than 2 months of cervico-thoraco-abdominal-pelvic CT and scintigraphy in OctréoScan®
...
staging of a known recurrence
Patients over 18 years
Patient who have received in a lower range than 2 months of cervico-thoraco-abdominal-pelvic CT and scintigraphy in OctréoScan®
Patient who is suspected of endocrine tumors according to symptomatology, biology or imaging or pathological context (multiple endocrine neoplasia type 1)
initial staging: this includes research multifocal disease or locoregional or metastatic extension if well-differentiated neuroendocrine tumor (grade 1 et/ou 2)
Patient affiliated or beneficiary of regime of social security of a Member State of the European community
Search occult recurrence or suspicion of recurrence (clinical, laboratory, imaging doubtful)
Search of the primary tumor, especially in the case of the inaugural discovery of metastases
Patient who have signed an informed consent

Exclusion Criteria

Pregnant or lactating woman
Persons placed under judicial protection
Patient with another evolutive cancer disease and/or treated for less than 5 years
...
Pregnant or lactating woman
Persons placed under judicial protection
Patient with another evolutive cancer disease and/or treated for less than 5 years
Patient unable to give their free and informed consent
Premenopausal woman without effective contraception (estrogen-progestin or intrauterine contraceptive device)

Tracking Information

NCT #
NCT02134639
Collaborators
Not Provided
Investigators
  • Principal Investigator: Philippe FERNANDEZ, Professor University Hospital, Bordeaux
  • Philippe FERNANDEZ, Professor University Hospital, Bordeaux